ESTRO meets Asia 2024 - Abstract Book

S38

Invited Speaker

ESTRO meets Asia 2024

Insurance program, 2) continue Advanced Medical Care, or 3) withdraw from Advanced Medical Care. In order to create evidence in clinical outcomes for Advanced Medical Care, JASTRO has organized all particle therapy facilities to conduct clinical research. Specifically, this includes multicenter prospective clinical trials, registry registration of all cases, and summarizing the results of existing treatments. In 2016, pediatric cancer for proton therapy and bone and soft tissue tumors for carbon-ion radiotherapy were covered by the Public Health Insurance for the first time, respectively. As of 2024, the following cancers were covered by the Public Health Insurance. Proton therapy: head and neck cancer, early stage lung cancer, hepatocellular carcinoma larger than 4 cm, intrahepatic cholangiocarcinoma, locally advanced pancreatic cancer, postoperative recurrence of rectal cancer, prostate cancer, bone and soft tissue tumor, paediatric cancer; Carbon-ion radiotherapy: head and neck cancer, early stage lung cancer, hepatocellular carcinoma larger than 4 cm, intrahepatic cholangiocarcinoma, locally advanced pancreatic cancer, postoperative recurrence of rectal cancer, prostate cancer, bone and soft tissue tumor, uterine cervical cancer, gynaecologic malignant melanoma. In my presentation, I will have a look at the 10-year approach of the national registry system under the leadership of JASTRO.

529

Current standard of care treatment in non-metastatic cervix cancer

Supriya Chopra

Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India

Abstract

Speaker will summarise the existing evidence in non metastatic cervical cancer describing the most recent advances in standard of care. This will include developments with IG-IMRT, Image Guided Brachytherapy. Newer studies with systemic therapy and immunotherapy in locally advanced cervical cancer and there results will be discussed along with the studies in pipeline. Newer avenues with translational research in cervical cancer will also be discussed.

530

Dose and fractionation

Karin Haustermans

Radiation Oncology, UZ KULeuven, Leuven, Belgium

Abstract

The way we irradiate prostate cancer today is very different from how we used to do it. There is evidence that the alpha/beta ratio of prostate cancer is very low. This means that prostate cancer is very fractionation-sensitive even more so than late-responding tissues. This makes it feasible to move from conventional fractionation to moderate hypofractionation or even ultrahypofractionation. Several phase 3 studies have shown that moderate hypofractionation gives equally good results as conventional fractionation. Recent data demonstrated ultrahypofractionation to be non-inferior to conventional radiotherapy for low- and intermediate-risk prostate cancer.